Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN42,8242,911,28
Msft217,51217,54-0,95
Nokia3,54453,5814,14
IBM126,1126,140,16
Daimler AG48,7448,755-1,19
PFE38,3138,320,97
19.10.2020 18:13:39
Indexy online
AD Index online
select
AD Index online
 

  • 19.10.2020 15:48:47
Mesoblast (US Other OTC (Pink Sheets))
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
2,29 4,57 -0,15 100
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.10.2020
Popis společnosti
Obecné informace
Název společnostiMesoblast limited
TickerMSB
Kmenové akcie:Fully Paid Ord. Shrs
RICMSB.AX
ISINAU000000MSB8
Poslední známé roční výsledky30.06.2020
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 30.06.2020 102
Akcie v oběhu k 30.06.2020 580 449 612
MěnaUSD
Kontaktní informace
UliceL 38 55 Collins St
MěstoMELBOURNE
PSČ3000
ZeměAustralia
Kontatní osobaSchond Greenway
Funkce kontaktní osobyIR Contact Officer
Telefon61 396 396 036
Fax61396396030
Kontatní telefon12 128 802 060

Business Summary: Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2020, Mesoblast limited revenues increased 92% to $32.2M. Net loss decreased 13% to $77.9M. Revenues reflect Milestone revenue increase from $11M to $25M, Commercialization revenue increase of 32% to $6.6M. Lower net loss reflects Remeasurement of contingent considerati decrease from $6.3M (expense) to $1.4M (income), Research and development - Balancing val decrease of 8% to $51.5M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 19.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorSilviu Itescu-
Non-Executive Independent Vice Chairman of the BoardWilliam Burns7301.09.201601.09.2016
Chief Financial OfficerJoshua Muntner4928.05.201828.05.2018
Chief Operating OfficerDagmar Rosa-Bjorkeson5623.07.202023.07.2020
Senior Vice President - CommercialEric Strati-19.12.201819.12.2018
General Counsel, Corporate ExecutivePeter Howard-
Chief Medical OfficerFred Grossman-19.08.201919.08.2019
Head of ManufacturingJohn McMannis-01.01.2011
Head of Research and New Product DevelopmentPaul Simmons-01.01.2011
Head of Regulatory Affairs and Quality ManagementGeraldine Storton-